SN.L - Smith & Nephew plc
| Previous close | 1,912.50 |
| Open | 1,905.00 |
| Bid | 1,917.50 x 0 |
| Ask | 1,918.50 x 0 |
| Day's range | 1,898.00 - 1,922.00 |
| 52-week range | 1,242.50 - 1,998.40 |
| Volume | 1,025,273 |
| Avg. volume | 2,347,405 |
| Market cap | 16.775B |
| Beta (3Y monthly) | 0.39 |
| PE ratio (TTM) | 24.07 |
| EPS (TTM) | 79.70 |
| Earnings date | 8 Feb 2018 - 13 Feb 2018 |
| Forward dividend & yield | 0.28 (1.52%) |
| Ex-dividend date | 2019-10-03 |
| 1y target est | 18.49 |
- Simply Wall St.
What To Know Before Buying Smith & Nephew plc (LON:SN.) For Its Dividend
Is Smith & Nephew plc (LON:SN.) a good dividend stock? How can we tell? Dividend paying companies with growing...
- Fool.co.uk
3 FTSE 100 companies that just raised their dividends
Dividend growth investing can be a profitable long-term investment strategy. Here's a look at three FTSE 100 (INDEXFTSE: UKX) companies that just hiked their dividend payouts.
- Fool.co.uk
Retirement saving: why I’d buy these 2 FTSE 100 shares in an ISA or SIPP today
I think these two FTSE 100 (INDEXFTSE:UKX) shares could deliver improving outlooks after contrasting recent performances.
- Simply Wall St.
Is Smith & Nephew (LON:SN.) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- Fool.co.uk
2 FTSE 100 dividend growth stocks I think could help you get rich, retire early and beat the State Pension
Royston Wild discusses two FTSE 100 (INDEXFTSE: UKX) stocks he reckons could make you rich in retirement. Read on!
- Simply Wall St.
Should Smith & Nephew plc's (LON:SN.) Recent Earnings Decline Worry You?
Examining how Smith & Nephew plc (LON:SN.) is performing as a company requires looking at more than just a years...
- Fool.co.uk
Have £3k to spend? A surging FTSE 100 stock I’d buy right now
Royston Wild zeroes in on a terrific FTSE 100 (INDEXFTSE: UKX) share that he thinks could make you richer in the coming years.
- Simply Wall St.
Will Smith & Nephew plc's (LON:SN.) Earnings Grow Over The Next Year?
Looking at Smith & Nephew plc's (LON:SN.) earnings update in December 2018, it seems that analyst forecasts are fairly...
- Simply Wall St.
Despite Its High P/E Ratio, Is Smith & Nephew plc (LON:SN.) Still Undervalued?
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
- Simply Wall St.
Estimating The Intrinsic Value Of Smith & Nephew plc (LON:SN.)
Does the June share price for Smith & Nephew plc (LON:SN.) reflect what it's really worth? Today, we will estimate the...
- Simply Wall St.
Need To Know: Smith & Nephew plc (LON:SN.) Insiders Have Been Selling Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
- Simply Wall St.
Do Directors Own Smith & Nephew plc (LON:SN.) Shares?
A look at the shareholders of Smith & Nephew plc (LON:SN.) can tell us which group is most powerful. Insiders often...
- Simply Wall St.
How Good Is Smith & Nephew plc (LON:SN.), When It Comes To ROE?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Business Wire
New NICE guidance recognises that Smith & Nephew’s PICO™ sNPWT provides better outcomes than standard dressings in patients at high risk of surgical site infections, at similar overall cost
LONDON--(BUSINESSWIRE)-- Smith & Nephew (NYSE:SNN; LSE:SN), the global medical technology business, welcomes the launch of new medical technologies guidance from the UK National Institute for Health and ...
- Reuters
Smith & Nephew lifts revenue view after best quarter since 2015
Emerging markets, especially China, have been a bright spot for the company as its mature markets, including the United States which accounts for about half of its revenue, stabilise after a shaky start to last year. Growth of 15.3 percent in emerging markets powered Smith & Nephew's total revenue to $1.20 billion (£919.4 million), in line with analysts' expectations, according to a company-compiled consensus http://www.smith-nephew.com/investor-centre/reporting/analyst-consensus. Demand from emerging markets will continue to lift the company as patient populations grow and medical expertise improves, Chief Executive Officer Namal Nawana told Reuters.
- Simply Wall St.
Why Fundamental Investors Might Love Smith & Nephew plc (LON:SN.)
Attractive stocks have exceptional fundamentals. In the case of Smith & Nephew plc (LON:SN.), there's is a notable dividend-paying company that has been able to sustain great financial health over t...
- Simply Wall St.
How Good Is Smith & Nephew plc (LON:SN.) At Creating Shareholder Value?
Today we'll look at Smith & Nephew plc (LON:SN.) and reflect on its potential as an investment. Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. F...
- Simply Wall St.
How Much Money Does Smith & Nephew plc (LON:SN.) Make?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you are currently a shareholder in Smith & Nephew plc (LON:SN.), or considering investing in the stock, you need to examin...
